Your search for supplemental oxygen returned 10 results

Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo

The studies evaluated routine clinical practice data from more than 800 hospitals in the US.

Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.

Investigators developed and validated a machine learning tool providing an early indication of disease progression in community-acquired pneumonia.

Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity

Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.

Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.

No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen

The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.

Findings showed that the trial did not meet statistical significance on the primary endpoint.